1. Appelbaum FR. Pursuing the goal of a donor for everyone in need. N Engl J Med. 2012;367(16):1555–1556. [PubMed] [Google Scholar]
2. Barker JN, Byam CE, Kernan NA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 2010;16(11):1541–1548. [PMC free article] [PubMed] [Google Scholar]
3. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA. 1989;86(10):3828–3832. [PMC free article] [PubMed] [Google Scholar]
4. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174–1178. [PubMed] [Google Scholar]
5. Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79(7):1874–1881. [PubMed] [Google Scholar]
6. Kohli-Kumar M, Shahidi NT, Broxmeyer HE, et al. Haemopoietic stem/progenitor cell transplant in Fanconi anaemia using HLA-matched sibling umbilical cord blood cells. Br J Haematol. 1993;85(2):419–422. [PubMed] [Google Scholar]
7. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995;346(8969):214–219. [PubMed] [Google Scholar]
8. Broxmeyer HE, Kurtzberg J, Gluckman E, et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells. 1991;17(2):313–329. [PubMed] [Google Scholar]
9. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773–4777. [PMC free article] [PubMed] [Google Scholar]
10. Vormoor J, Lapidot T, Pflumio F, Risdon G, Patterson B, Broxmeyer HE, Dick JE. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood. 1994;83(9):2489–2497. [PubMed] [Google Scholar]
11. Bock TA, Orlic D, Dunbar CE, Broxmeyer HE, Bodine DM. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med. 1995;182(6):2037–2043. [PMC free article] [PubMed] [Google Scholar]
12. Broxmeyer HE, Gluckman E, Auerbach A, et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning. 1990;8(Suppl 1):76–89, discussion 89-91. [PubMed] [Google Scholar]
13. Carow CE, Hangoc G, Cooper SH, Williams DE, Broxmeyer HE. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential. Blood. 1991;78(9):2216–2221. [PubMed] [Google Scholar]
14. Lu L, Xiao M, Shen RN, Grigsby S, Broxmeyer HE. Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood. 1993;81(1):41–48. [PubMed] [Google Scholar]
15. Carow CE, Hangoc G, Broxmeyer HE. Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. Blood. 1993;81(4):942–949. [PubMed] [Google Scholar]
16. Broxmeyer HE, Hangoc G, Cooper S, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA. 1992;89(9):4109–4113. [PMC free article] [PubMed] [Google Scholar]
17. Auerbach AD, Liu Q, Ghosh R, Pollack MS, Douglas GW, Broxmeyer HE. Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion. 1990;30(8):682–687. [PubMed] [Google Scholar]
18. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1983;54(3):431–440. [PubMed] [Google Scholar]
19. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86(7):2856–2862. [PubMed] [Google Scholar]
20. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339(22):1565–1577. [PubMed] [Google Scholar]
21. Gluckman E, Ruggeri A, Rocha V, et al. Family-directed umbilical cord blood banking. Haematologica. 2011.96:(11):1701-1707. [PMC free article] [PubMed]
22. Gluckman E, Rocha V, Boyer-Chammard A, et al. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337(6):373–381. [PubMed] [Google Scholar]
23. Rocha V, Wagner JE, Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med. 2000;342(25):1846–1854. [PubMed] [Google Scholar]
24. Herr AL, Kabbara N, Bonfim CM, et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood. 2010;116(11):1849–1856. [PubMed] [Google Scholar]
25. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335(3):157–166. [PubMed] [Google Scholar]
26. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611–1618. [PubMed] [Google Scholar]
27. Gluckman E, Rocha V, Arcese W, et al. Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004;32(4):397–407. [PubMed] [Google Scholar]
28. Locatelli F, Rocha V, Chastang C, et al. Eurocord-Cord Blood Transplant Group. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood. 1999;93(11):3662–3671. [PubMed] [Google Scholar]
29. Bizzetto R, Bonfim C, Rocha V, et al. Eurocord and SAA-WP from EBMT. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. 2011;96(1):134–141. [PMC free article] [PubMed] [Google Scholar]
30. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88(3):795–802. [PubMed] [Google Scholar]
31. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97(10):2962–2971. [PubMed] [Google Scholar]
32. Fernandes JF, Rocha V, Labopin M, et al. Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119(12):2949–2955. [PubMed] [Google Scholar]
33. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947–1954. [PubMed] [Google Scholar]
34. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2007;13(4):444–453. [PubMed] [Google Scholar]
35. Ruggeri A, Eapen M, Scaravadou A, et al. Eurocord Registry; Center for International Blood and Marrow Transplant Research; New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17(9):1375–1382. [PMC free article] [PubMed] [Google Scholar]
36. Gluckman E, Rocha V, Ionescu I, et al. Eurocord-Netcord and EBMT. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant. 2007;13(9):1073–1082. [PubMed] [Google Scholar]
37. Wagner JE, Eapen M, Carter SL, et al. No survival advantage after double vs single cord blood transplantation in children with hematologic malignancy. Blood. 2012;120(21):359a. [abstract] [Google Scholar]
38. Ballen KK, Klein JP, Pedersen TL, et al. Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012;18(6):903–912. [PMC free article] [PubMed] [Google Scholar]
39. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815–1822. [PubMed] [Google Scholar]
40. Cohen YC, Scaradavou A, Stevens CE, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 2011;46(1):70–76. [PMC free article] [PubMed] [Google Scholar]
41. Robin M, Sanz GF, Ionescu I, et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia. 2011;25(1):75–81. [PubMed] [Google Scholar]
42. Sanz J, Boluda JC, Martín C, et al. Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH) Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant. 2012;47(10):1287–1293. [PubMed] [Google Scholar]
43. Ooi J, Takahashi S, Tomonari A, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2008;14(12):1341–1347. [PubMed] [Google Scholar]
44. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regiment workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Bone Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15(3):367–369. [PMC free article] [PubMed] [Google Scholar]
45. Bacigalupo A, Ballen KK, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633. [PMC free article] [PubMed] [Google Scholar]
46. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102(5):1915–1919. [PubMed] [Google Scholar]
47. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13(1):82–89. [PMC free article] [PubMed] [Google Scholar]
48. Rocha V, Mohty M, Gluckman E, Rio B Eurocord; Reduced-Intensity Conditioning Subcommittee of the Acute Leukaemia Working Party; French Society of Bone Marrow Transplantation and Cellular Therapy. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Curr Opin Oncol. 2009;21(Suppl 1):S31–S34. [PubMed] [Google Scholar]
49. Cutler C, Stevenson K, Kim HT, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011;46(5):659–667. [PMC free article] [PubMed] [Google Scholar]
50. Rocha V, Labopin M, Ruggeri A, et al. Outcomes after Double Cord Blood Transplant compared to single cord blood transplant in adults with hematologic malignancy [abstract]. Blood. 2012; 120(21): 242a.
51. Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752–758. [PMC free article] [PubMed] [Google Scholar]
52. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117(8):2332–2339. [PMC free article] [PubMed] [Google Scholar]
53. Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. Br J Haematol. 2011;154(4):441–447. [PubMed] [Google Scholar]
54. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115(9):1843–1849. [PMC free article] [PubMed] [Google Scholar]
55. Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118(25):6691–6697. [PMC free article] [PubMed] [Google Scholar]
56. Ruggeri A, Rocha V, Masson E, et al. Impact of donor specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation. A Eurocord, Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis [published online ahead of print December 14, 2012]. Haematologica. 2012 [PMC free article] [PubMed] [Google Scholar]
57. Takanashi M, Atsuta Y, Fujiwara K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116(15):2839–2846. [PubMed] [Google Scholar]
58. Rocha V, Spellman S, Zhang MJ, et al. Eurocord-European Blood and Marrow Transplant Group and the Center for International Blood and Marrow Transplant Research. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012;18(12):1890–1896. [PMC free article] [PubMed] [Google Scholar]
59. van Rood JJ, Stevens CE, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci USA. 2009;106(47):19952–19957. [PMC free article] [PubMed] [Google Scholar]
60. Eapen M, Klein JP, Sanz GF, et al. Eurocord-European Group for Blood and Marrow Transplantation; Netcord; Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12(13):1214–1221. [PMC free article] [PubMed] [Google Scholar]
61. Garfall A, Kim H, Cutler C, et al. Allele level matching at HLA-C or DRB1 is associated with improved survival after reduced intensity cord blood transplantation. Blood. 2012;120(21):2010a. [abstract] [Google Scholar]
62. Willemze R, Rodrigues CA, Labopin M, et al. Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23(3):492–500. [PMC free article] [PubMed] [Google Scholar]
63. Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009;113(22):5628–5634. [PMC free article] [PubMed] [Google Scholar]
64. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012;119(9):1972–1980. [PubMed] [Google Scholar]
65. Eapen M, Rocha V, Sanz G, et al. Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–660. [PMC free article] [PubMed] [Google Scholar]
66. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–4699. [PMC free article] [PubMed] [Google Scholar]
67. Ponce DM, Zheng J, Gonzales AM, et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(9):1316–1326. [PMC free article] [PubMed] [Google Scholar]
68. Chen YB, Aldridge J, Kim HT, et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012;18(5):805–812. [PubMed] [Google Scholar]
69. Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012;119(23):5591–5598. [PMC free article] [PubMed] [Google Scholar]
70. Brunstein CG, Fuchs EJ, Carter SL, et al. Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288. [PMC free article] [PubMed] [Google Scholar]
71. Broxmeyer HE, Cooper S, Hass DM, Hathaway JK, Stehman FB, Hangoc G. Experimental basis of cord blood transplantation. Bone Marrow Transplant. 2009;44(10):627–633. [PubMed] [Google Scholar]
72. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118(24):6438–6445. [PMC free article] [PubMed] [Google Scholar]
73. Bautista G, Cabrera JR, Regidor C, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant. 2009;43(5):365–373. [PubMed] [Google Scholar]
74. Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–839. [PubMed] [Google Scholar]
75. Brunstein CG, Barker JN, Weisdorf DJ, et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009;43(12):935–940. [PMC free article] [PubMed] [Google Scholar]
76. Rocha V, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematologic malignancies [published online ahead of print March 15, 2013]. Transplantation. 2013 [PubMed] [Google Scholar]
77. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232–236. [PMC free article] [PubMed] [Google Scholar]
78. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367(24):2305–2315. [PMC free article] [PubMed] [Google Scholar]
79. Horowitz ME, Stiff PJ, Chao NJ, et al. Nicord expanded hematpoietic progenitor cells (HPC) are capable of outcompeting the unmanipulated cord blood unit and of prolonged myeloid and lymphoid engraftment following myeloablative dual umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2013;19:S119–S128. [abstract] [Google Scholar]
80. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345–1348. [PMC free article] [PubMed] [Google Scholar]
81. Rohrabaugh SL, Campbell TB, Hangoc G, Broxmeyer HE. Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice. Blood Cells Mol Dis. 2011;46(4):318–320. [PMC free article] [PubMed] [Google Scholar]
82. Robinson SN, Simmons PJ, Thomas MW, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol. 2012;40(6):445–456. [PMC free article] [PubMed] [Google Scholar]
83. Christopherson KW, II, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686):1000–1003. [PubMed] [Google Scholar]
84. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 2007;16(3):347–354. [PubMed] [Google Scholar]
85. Cutler CS, Shoemaker D, Ballen KK, et al. FT 1050(16,16 dimethyl Prostaglandin E2)-enhanced umbilical cord blood accelerates hematopoietic engraftment after reduced intensity conditioning and double umbilical cord blood transplantation. Blood. 2011;118:653a. [abstract] [Google Scholar]
86. Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell. 2011;8(4):445–458. [PMC free article] [PubMed] [Google Scholar]
87. Farag SS, Srivastava S, Messina-Graham S, et al. In-vivo inhibition to enhance engraftment of single-unit cord blood transplants in adults with high-risk hematological malignancies. Stem Cells Dev. 2013;22(7):1007-1015. [PMC free article] [PubMed]
88. Broxmeyer HE, Hoggatt J, O’Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786–1796. [PMC free article] [PubMed] [Google Scholar]
89. Broxmeyer HE, editor. Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press; 2011. [Google Scholar]
90. Broxmeyer HE, Farag SS, Rocha V. Cord Blood Hematopoietic Cell Transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Antin JH, editors. Thomas' Hematopoietic Cell Transplantation. 5th ed. Oxford, England: Wiley Blackwell; 2013. [Google Scholar]
91. Ballen KK, Cutler C, Yeap BY, et al. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(7):1025–1031. [PMC free article] [PubMed] [Google Scholar]
92. Sauter C, Abboud M, Jia X, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant. 2011;17(10):1460–1471. [PMC free article] [PubMed] [Google Scholar]
93. Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell. 2010;6(1):21–24. [PubMed] [Google Scholar]
94. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481(7381):295–305. [PMC free article] [PubMed] [Google Scholar]
95. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109(3):1322–1330. [PubMed] [Google Scholar]
96. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Japan Cord Blood Bank Network. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113(8):1631–1638. [PubMed] [Google Scholar]
